Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review
Declaration of conflict of interest: The authors declare no conflicts of interest.
Log in with Open Athens, Shibboleth, or your institutional credentials.
If you have previously obtained access with your personal account, Please log in.
If you previously purchased this article, Log in to Readcube.
You previously purchased this article on READCUBE_PURCHASE_DATE. Click on an option below to access.
Logged in as READCUBE_USER. Log out of ReadCube.
Abstract
Background and Aim
Proton pump inhibitors (PPIs) are among the most widely used medications worldwide. Dementia is an increasingly common cause of disability in older populations. Recent studies have suggested an increased risk of cognitive impairment and dementia diagnosis among people who consume PPIs. This systematic review explores dementia, cognitive impairment, and the use of PPIs.
Methods
Systematic searches were conducted in the databases of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), PSYCinfo, Scopus, Web of Science, and ClinicalTrials.gov for articles published from inception to June 30, 2016. Primary outcomes of interest were the use of PPIs and diagnosis of dementia or acute cognitive impairment. Studies conducted on people aged less than 18 years old were excluded. All study designs were eligible for inclusion. Two reviewers independently assessed study quality and extracted data from included studies.
Results
The systematic search strategy and screening process yielded 11 studies for inclusion in the systematic review. Four studies explored PPI use and dementia, and seven studies explored PPI use and acute cognitive impairment. Three of the four studies exploring dementia identified a positive association with PPI use. A positive association was also observed in the majority of studies exploring acute cognitive impairment.
Conclusions
Based on the current published literature, this systematic review has identified that the reported association between PPI use and dementia is limited by methodological issues and conflicting results. Further longitudinal studies with robust bias limitation are required to explore the use of PPIs and dementia or acute cognitive impairment, and to ascertain the existence of any causal relationships.
Number of times cited according to CrossRef: 7
- Fabrizia Lattanzio and Andrea Corsonello, Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: are they safe?, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2018.10.008, (2018).
- Riley Batchelor, Radya Kumar, Julia F. M. Gilmartin‐Thomas, Ingrid Hopper, William Kemp and Danny Liew, Systematic review with meta‐analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel, Alimentary Pharmacology & Therapeutics, 48, 8, (780-796), (2018).
- Sagar Dugani, Jeffrey M. Ames, JoAnn E. Manson and Samia Mora, Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach, Current Atherosclerosis Reports, 10.1007/s11883-018-0717-y, 20, 3, (2018).
- David John Wright, Sion Scott, Jackie Buck and Debi Bhattacharya, Role of nurses in supporting proactive deprescribing, Nursing Standard, 10.7748/ns.2019.e11249, (2018).
- Laura M. Dominguez, Raymond J. Brown and C. Blake Simpson, Treatment Outcomes of In-Office KTP Ablation of Vocal Fold Granulomas, Annals of Otology, Rhinology & Laryngology, 10.1177/0003489417738790, 126, 12, (829-834), (2017).
- Michal Novotny, Blanka Klimova and Martin Valis, PPI Long Term Use: Risk of Neurological Adverse Events?, Frontiers in Neurology, 10.3389/fneur.2018.01142, 9, (2019).
- T.N. Poly, M.M. Islam, H.-C. Yang, C.C. Wu and Y.-C.(.J.). Li, Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies, Osteoporosis International, 10.1007/s00198-018-4788-y, (2018).
